Updated

Scientists reported on November 3, 2026 that a drug originally developed for spinal cord injuries can address several key features of Alzheimer's disease, including DNA damage and brain inflammation. The experimental treatment has already undergone initial safety testing in humans, which could offer a faster path toward therapies that target the disease at its roots.